Document:

8-K filed by Biovest International, Inc

 UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION 
 Washington, D.C. 20549 
  

 FORM 8-K 
  

 CURRENT REPORT 
 Pursuant to Section 13 or 15(d) of the 
 Securities Exchange Act of 1934 
 Date of Report (Date of earliest event reported): September 11, 2007 
  

 BIOVEST INTERNATIONAL, INC. 
 (Exact
name of Registrant as Specified in its Charter) 
  

  

					
	Delaware	 	0-11480	 	41-1412084
	 (State or other jurisdiction of
 incorporation or organization)
	 	(Commission File Number)	 	 (I.R.S. Employer
 Identification No.)

 377 Plantation Street 
 Worcester, Massachusetts 01605 
 (Address of Principal Executive Offices; Zip
Code) 
 Registrant’s telephone number, including area code: (508) 793-0001 
  

 Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
  

	 ̈	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

  

	 ̈	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

  

	 ̈	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2-(b)) 

  

	 ̈	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

  

 BIOVEST INTERNATIONAL, INC. 
 FORM 8-K 
  

	Item 1.01.	Entry Into a Material Definitive Agreement. 

 On September 11,
2007, the Company entered into loan documentation for two financing transactions with Directors of the Company, as follows: 
  

	 	•	 	 The Company issued an Unsecured Promissory Note in the amount of $100,000 to Francis E. O’Donnell, Jr. M.D., a Director and Vice-Chairman of the Company and
Chairman and CEO of the Company’s parent, Accentia Biopharmaceuticals, Inc., in consideration of a loan in the principal amount of $100,000 to be used by the Company for operating expenses. This unsecured Note bears interest at prime rate plus
2%, is non-amortizing and payable in a single lump sum of principal and accrued interest at maturity, and will mature at the earlier of the date of closing of a sale of non-strategic assets of the Company with net proceeds of $5 million or greater
or one year from the date of the Note. 

  

	 	•	 	 The Company issued an Unsecured Promissory Note in the amount of $100,000 to Ronald Osman, a Director of the Company in consideration of a loan in the principal
amount of $100,000 to be used by the Company for operating expenses. This unsecured Note bears interest at prime rate plus 2%, is non-amortizing and payable in a single lump sum of principal and accrued interest at maturity, and will mature at the
earlier of the date of closing of a sale of non-strategic assets of the Company with net proceeds of $5 million or greater or one year from the date of the Note. In addition, the Company agreed to issue to Mr. Osman a Warrant to purchase up to
909,090 shares of the Company’s common stock at an exercise price of $1.10 per share. The exercise price may be paid by Mr. Osman in cash or through a cashless exercise by surrendering a portion of the warrant or underlying warrant shares
with a fair market value at the time of exercise equal to the exercise price. The warrant will expire on September 5, 2014. 

 Also on
September 11, 2007, the Company entered into loan documentation for a financing transaction with Philip Rosensweig, an individual investor, as follows: 
  

	 	•	 	 The Company issued a Subordinated Promissory Note in the amount of $300,000 (the “Subordinated Note”) to Mr. Rosensweig pursuant to a Note
Purchase Agreement (the “Purchase Agreement”). This Subordinated Note is non-interest bearing and non-amortizing and payable in a single lump sum of principal at maturity. The Subordinated Note will mature one year from the date of
issuance of the Subordinated Note. 

  

	 	•	 	 Pursuant to the Purchase Agreement, upon maturity of the Subordinated Note, the Company has agreed to issue to Mr. Rosensweig shares of the Company’s
common stock valued at $300,000, priced at the lower of $1.10 per share or a 15% discount to the volume weighted average price of the Company’s common stock over the 60 days preceding maturity, with limitation as to the minimum price.

  

 2 

 The Company has entered into an understanding with Pulaski Bank and Trust Company of St. Louis (“Pulaski”)
whereby Pulaski has agreed to extend the maturity date on the Company’s existing Promissory Note in the principal amount of $1,000,000 (the “$1,000,000 Note”) through October 5, 2007 and to defer the payment of certain renewal
fees through and until the maturity date of both the $1,000,000 Note and the Company’s existing Promissory Note in the principal amount of $750,000 (the “$750,000 Note”), which matures on September 21, 2007. In consideration
of these extensions and deferrals, the Company has agreed to issue to Pulaski a Warrant to purchase up to 67,282 shares of the Company’s common stock at an exercise price of $1.10 per share, fully vested upon issuance with a five-year
term. In addition, the Company has agreed to make immediate payment to Pulaski of all interest due on both the $1,000,000 Note and the $750,000 Note through their respective maturity dates. The parties are in the process of reducing the
understanding to writing. 
 Each of the notes, shares and warrants described above were issued by the Company as described above in transactions that were
exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D under the Securities Act. Such sale and
issuance did not involve any public offering, was made without general solicitation or advertising, and all parties to the transactions are accredited investors with access to all relevant information necessary to evaluate the investment and
represented to us that the Notes and Warrants were being acquired for investment. 
  

	Item 2.03.	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registration. 

 The information included in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 2.03. 
  

	Item 3.02.	Unregistered Sales of Equity Securities. 

 The information included
in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02. 
  

 3 

 Signature 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ James A. McNulty

		 	James A. McNulty,
		 	Chief Financial Officer

 Date: September 12, 2007 
  

 4Employment Agreement

 Exhibit 10.246 
 Portions of the exhibit marked [*] are omitted and are requested to be treated confidentially. 
 EMPLOYMENT AGREEMENT

 THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into
on this 12th day of September, 2007, to be effective on the 1st day of October, 2007 (the “Effective Date”), by and between Pharmaceutical
Product Development, Inc., a North Carolina corporation (the “Company”), with a mailing address for notice purposes of 929 North Front Street, Wilmington, North Carolina 28401, Attention: Fred N. Eshelman, and Daniel G. Darazsdi
(“Employee”), an individual whose mailing address for notice purposes is 929 North Front Street, Wilmington, North Carolina 28401. 
 RECITALS 
 A. The Company is a clinical research organization engaged in the business of providing drug discovery and
development services to pharmaceutical, biotechnology, medical device, government and academic organizations throughout the world (the “Business”). 
 B. The Company desires to employ Employee and Employee desires to be employed by the Company, all upon the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the mutual covenants of the parties hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE 1 
 EMPLOYMENT AND DUTIES 
 1.1
Employment of Employee. On the Effective Date, the Company agrees to employ Employee and Employee accepts such employment pursuant and subject to the terms and conditions of this Agreement. 
 1.2. Duties and Powers. During the Employment Period (as defined herein), Employee shall serve as Chief Financial Officer of the Company and will
have such responsibilities, duties and authority, and will render such services for and in connection with the Company and its affiliates as are customary in such position and as the Board of Directors of the Company (the “Board”) and the
Chief Executive Officer of the Company shall from time to time reasonably direct. Employee shall devote Employee’s full business time and attention exclusively to the Business of the Company and shall use best efforts to faithfully carry out
Employee’s duties and responsibilities hereunder. Employee shall comply with all personnel policies and procedures of the 

 
Company as the same now exist or may be hereafter implemented by the Company from time to time, including those policies contained in the Company’s
employee manual or handbook which sets forth policies and procedures generally for employees of the Company and its subsidiaries and affiliates (the “Handbook”) to the extent not inconsistent with this Agreement. 
 ARTICLE 2 
 TERM OF EMPLOYMENT

 Unless sooner terminated as provided elsewhere in this Agreement, Employee’s employment under this Agreement shall begin the
Effective Date and end at 11:59 p.m. Eastern Time on September 30, 2009 (“Initial Employment Period”). This Agreement shall automatically renew for successive one-year periods, unless either the Company or Employee provides written
notice to the other at least 60 days prior to the termination of the Initial Employment Period or any renewal period stating said party’s desire to terminate this Agreement. The Initial Employment Period and any extension or renewal thereof
shall be referred to herein together as the “Employment Period”. Notwithstanding anything to the contrary contained herein, the Employment Period is subject to termination pursuant to Article 4 hereof. 
 ARTICLE 3 
 COMPENSATION AND BENEFITS 

 3.1 Base Salary. The Company will pay Employee an annual base salary at a rate of $350,000 per annum (the “Base Salary”),
payable in accordance with the Company’s regular payroll policy for salaried employees. The Base Salary of Employee may be subject to increase annually during the Employment Period by the Company. If the Employment Period is terminated pursuant
to Article 4 hereof or is otherwise shorter than a full contract year, then the Base Salary for any partial year will be prorated based on the number of days elapsed in such year during which services were actually performed by Employee. 

3.2 Sign-On Bonus. The Company will pay Employee a one-time bonus of $75,000 in cash within thirty (30) days of the Effective Date in
accordance with the terms of a separate sign-on bonus agreement to be entered into simultaneously with this Agreement. 
 3.3
Benefits. 
 a. During the Employment Period, Employee shall be eligible to participate in and/or receive benefits under the health
insurance, group term life/AD&D, short and long-term disability, retirement, paid-time off and other plans maintained from time to time by the Company, subject in each instance to Employee meeting all eligibility and qualification requirements
of such plans. During the 

 
Employment Period, Employee shall be entitled to twenty-seven (27) days of paid-time-off, subject to the provisions of the Handbook. 
 b. In addition to the benefits provided in (a) above, during the Employment Period, Employee shall be entitled to participate in (i) the
employee incentive compensation plan maintained for employees of the Company, as the same may be amended from time to time (the “Incentive Compensation Plan”), and (ii) the 1995 Equity Compensation Plan maintained by PPD, as the same
has been and may be amended from time to time, or any successor plan (the “ECP”), subject in each instance to Employee meeting all eligibility and qualification requirements of such plans. For the calendar year 2007, Employee shall be paid
a bonus under the Incentive Compensation Plan in the fixed amount of $43,750. The Company will pay such bonus to Employee at the same time that it pays other bonuses under the Employee Incentive Compensation Plan. 
 3.4 Initial Stock Option Grant. The Company shall grant to Employee as of the Effective Date non-qualified options to purchase 90,000 shares of
PPD’s common stock. Said stock options shall be granted under the terms and conditions of the ECP and the Company’s standard Terms and Conditions for stock option awards. In addition, said stock options shall be subject to a three-year
linear vesting schedule and will be priced based on the Nasdaq closing price on the later of the Effective Date or the date on which the Compensation Committee of PPD’s Board of Directors approves the grant. 
 3.5 Restricted Stock Grant. The Company shall grant to Employee as of the Effective Date a restricted stock award for 10,000 shares of PPD’s
common stock. Said restricted stock award shall be granted under the terms and conditions of the ECP and the Company’s standard Restricted Stock Award Agreement to be entered into by PPD and Employee as of the Effective Date. In addition to the
other terms and conditions of the ECP and the Restricted Stock Award Agreement, said restricted stock award shall be subject to a three-year linear vesting schedule. 
 3.6 Expenses. The Company will reimburse Employee, in accordance with and subject to Employee’s compliance with the Company’s policy, for Employee’s necessary and reasonable out-of-pocket
expenses incurred in the course of performance of Employee’s duties hereunder. All reimbursement of expenses to Employee hereunder shall be conditioned upon presentation of sufficient documentation evidencing such expenses. 
 3.7 Working Facilities. Employee shall work out of the Company’s principal offices in Wilmington, North Carolina. The Company shall furnish
Employee with such office space, equipment, technical, secretarial and clerical assistance and such other facilities, services and supplies as shall be reasonably necessary to enable Employee to perform the duties required of Employee hereunder in
an efficient and professional manner. 

 3.8 Use of Aircraft. Employee shall be entitled to use the Company’s aircraft for personal
use up to a maximum of 5,000 miles per year, subject to the terms and conditions of the Company’s aircraft policy as the same may be amended from time to time. 
 ARTICLE 4 
 TERMINATION OF EMPLOYMENT 
 4.1 Basis for Termination. Notwithstanding any other provision in this Agreement to the contrary, the Employment Period and Employee’s
employment hereunder shall terminate effective on the date indicated upon the happening of any of the following events: 
 a. Upon the death
of Employee, effective immediately on the date of death without any notice; 
 b. Upon a determination by the Chief Executive Officer of
PPD, acting in good faith and not in an arbitrary or capricious manner, but made in his sole discretion, that Employee has become physically or mentally incapacitated, as determined under the Company’s short-term disability policy, and is
unable to perform his duties under this Agreement as a result of such disability, which inability continues for a period of sixty (60) days during any twelve-month period hereunder, effective upon the date said determination is communicated to
Employee or such later date as specified by the Chief Executive Officer of PPD; or 
 c. Upon a determination by the Chief Executive Office
of PPD, acting in good faith but made in his sole discretion, that Employee: (i) has failed to substantially perform his duties under or otherwise breached any of the material terms of this Agreement; (ii) has demonstrated negligence or
willful misconduct in the execution of his duties; or (iii) has been convicted of a felony; in each case effective upon the date said determination is communicated to Employee or such later date as specified by the Chief Executive Officer of
PPD. 
 4.2 Compensation After Termination During Employment Period. 
 a. If the Company terminates Employee’s employment during the Employment Period pursuant to Section 4.1.a, Section 4.1.b or
Section 4.1.c hereof, or if Employee terminates this Agreement pursuant to Article 2 hereof or otherwise terminates his employment with the Company, then the Company shall have no further obligations hereunder or otherwise with respect to
Employee’s employment from and after the termination or expiration date, as the case may be, except that the Company shall pay Employee’s unpaid Base Salary accrued through the date of termination or expiration and shall provide such
benefits as are required by applicable law. From and after such termination or expiration date, the Company shall continue to have all other rights 

 
available hereunder, including without limitation all rights under Article 6 hereof, the Proprietary Agreement (as hereinafter defined), and at law or in
equity. 
 b. If at any time during the Employment Period the Company notifies Employee that it desires to terminate this Agreement pursuant
to Article 2 hereof or otherwise terminates Employee’s employment for any reason other than pursuant to Section 4.1.a, Section 4.1.b or Section 4.1.c hereof, then the Company shall have no further obligations hereunder or
otherwise with respect to Employee’s employment from and after the termination or expiration date, as the case may be, except that the Company shall: (i) continue to pay Employee’s Base Salary in effect as of the date of termination
or expiration for a period equal to the greater of (A) the number of months remaining in the then current term of this Agreement or (B) twelve (12) months from the date of termination or expiration; and (ii) provide such benefits
as are required by applicable law; provided, however, that in the event Employee obtains full-time employment elsewhere, Employee shall promptly notify the Company in writing thereof and the Company’s obligation to continue to pay
Employee’s Base Salary as provided in this sentence shall terminate as of the initial date of such employment. From and after such termination or expiration date, the Company shall continue to have all other rights available hereunder,
including without limitation all rights under Article 6 hereof, the Proprietary Agreement, and at law or in equity. 
 ARTICLE 5 

PROPRIETARY INFORMATION 
 Prior to
or coincident with the commencement date of this Agreement, Employee shall execute and deliver to the Company its standard Proprietary Information and Inventions Agreement (the “Proprietary Agreement”), a copy of which is attached hereto
as Annex A. 
 ARTICLE 6 
 NON-COMPETITION COVENANT 
 6.1 Non-Competition Covenant. Beginning on the Effective Date and continuing for a period
of [*] following the effective date of the termination (the “Termination Date”) of Employee’s employment with the Company for any reason, including, without limitation, termination pursuant to Article 2 hereof (the
“Non-Competition Period”), Employee will not (other than for the direct and sole benefit of the Company pursuant to this Agreement), directly or indirectly, either as an individual, as an officer, director, employee, shareholder,
consultant, contractor, partner, joint venturer, agent, or equity owner of any person, firm, corporation, partnership, limited liability company, trust or other business entity, or in any other capacity whatsoever, engage in any activity that is in
competition with the Business of the Company in any location in the world. Notwithstanding the foregoing, the Company agrees that (i) this Section 6.1 shall not prohibit Employee from working for a pharmaceutical, biotechnology or medical
device organization that is not a clinical research organization or otherwise competing 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

 
with the Business by providing drug discovery or development services to third parties on a fee for service basis and (ii) that Employee may own up to
two percent (2%) of the outstanding voting securities of any publicly-traded company that is engaged in a business activity prohibited by this Section 6.1 so long as the Employee does not otherwise participate in such business in any way
prohibited by this Section 6.1. 
 6.2 Reasonableness of Restrictions; Reformation. Employee acknowledges and agrees that the
Company conducts the Business and services clients of the Business throughout the world, and that its ability to do so is not based on its geographic location. In addition, Employee acknowledges and agrees that the geographic scope of the
non-competition covenants in Section 6.1 above are reasonable and no broader than necessary to protect the legitimate business interests of the Company and its affiliates, as applicable. Employee further acknowledges and agrees that the scope
of the prohibited activities and time duration in this Article 6 are reasonable in nature, are no broader than necessary to protect the legitimate business interests of the Company and its affiliates, and that irreparable injury will result to the
Company or its affiliates if the Employee breaches the provisions of this Article 6. Therefore, if Employee breaches any of the provisions of this Article 6, notwithstanding any other provision of this Agreement to the contrary, the Company shall be
entitled to immediate temporary injunctive and other equitable relief, without bond and without the necessity of showing actual monetary damages, subject to hearing as soon thereafter as possible. Nothing contained herein shall be construed as
prohibiting the Company from pursuing any other remedies available to it for such breach by Employee, including the recovery of any damages which it is able to prove. If a court of competent jurisdiction determines that any portion of this Article 6
is invalid or unenforceable, the remainder of this Article 6 shall not thereby be affected and shall be given full effect without regard to the invalid provisions. If any court of competent jurisdiction construes any of the provisions of this
Article 6, or any part thereof, to be unreasonable because of the duration or scope of such provision, such court shall have the power to reduce the duration or scope of such provision and to enforce such provision as so reduced. 
 6.3 Jurisdiction and Venue. The parties agree that the United States District Court for the Eastern District of North Carolina (sitting in
Wilmington, North Carolina) shall have exclusive jurisdiction to enforce the covenants under this Article 6 and to otherwise resolve any disputes or controversies under this Article 6. If such court lacks jurisdiction over any such proceeding, the
parties agree that the North Carolina Superior Court in New Hanover County, North Carolina shall have exclusive jurisdiction to enforce the covenants under this Article 6 and to otherwise resolve any disputes or controversies under this Article 6.
The parties agree that venue in either of such courts is proper and waive any claims and/or defenses based on improper venue. 
 ARTICLE 7

 MISCELLANEOUS 

 7.1 Withholding Taxes. All amounts payable under this Agreement, whether such payment is to be
made in cash or other property, shall be subject to applicable withholding requirements for Federal, state and local income taxes, employment and payroll taxes, and other legally required withholding taxes and contributions to the extent appropriate
in the determination of the Company, and Employee shall report all such amounts as ordinary income on Employee’s personal income returns and for all other purposes. 
 7.2 Assignment. No party hereto may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other party hereto; provided, however, that the Company shall have the
right to assign all or any part of its rights and obligations under this Agreement (i) to any member, subsidiary or affiliate of the Company or any surviving entity following any merger or consolidation of any of those entities with any entity
other than the Company, or (ii) in connection with the sale of the Business by the Company. 
 7.3 Binding Effect. All covenants
and agreements contained in this Agreement by or on behalf of any of the parties hereto shall be binding upon and inure to the benefit of the respective legal representatives, heirs, successors and permitted assigns of the parties hereto.

 7.4 Entire Agreement. This Agreement sets forth the entire understanding of the parties and supersedes and preempts all prior oral
or written understandings and agreements with respect to the subject matter hereof. 
 7.5 Severability. Whenever possible, each
provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. 
 7.6 Amendment;
Modification. No amendment or modification of this Agreement and no waiver by any party of the breach of any covenant contained herein shall be binding unless executed in writing by the party against whom enforcement of such amendment,
modification or waiver is sought. No waiver shall be deemed a continuing waiver or a waiver in respect of any subsequent breach or default, either of a similar or different nature, unless expressly so stated in writing. 
 7.7 Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of North Carolina,
without giving effect to provisions thereof regarding conflict of laws. 
 7.8 Arbitration. Except for disputes, controversies or
claims under Article 6 and the Proprietary Agreement, any dispute, controversy or claim arising out of or relating to this Agreement, including but not limited to its existence, validity, 

 
interpretation, performance or non-performance or breach, shall be decided by a single neutral arbitrator agreed upon by the parties hereto in Wilmington,
North Carolina in binding arbitration pursuant to the commercial arbitration rules of the American Arbitration Association then in effect. The parties to any such arbitration shall be limited to the parties to this Agreement or any successor
thereof. The written decision of the arbitrator shall be final and binding and may be entered and enforced in any court of competent jurisdiction. Each party waives any right to a jury trial in any such forum. Each party to the arbitration shall pay
its fees and expenses, unless otherwise determined by the arbitrator. 
 7.9 Notices. All notices, demands or other communications to
be given or delivered hereunder or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been properly served if (a) delivered personally, (b) delivered by a recognized overnight courier service,
(c) sent by certified mail, return receipt requested and first class postage prepaid, or (d) sent by facsimile transmission followed by a confirmation copy delivered by a recognized overnight courier service the next day. Such notices,
demands and other communications shall be sent to the address first set forth above, or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Date of service
of such notice shall be (i) the date such notice is personally delivered or sent by facsimile transmission (with issuance by the transmitting machine of a confirmation of successful transmission), (ii) the date of receipt if sent by
certified mail, or (iii) the date of receipt if sent by overnight courier. 
 7.10 Counterparts. This Agreement may be executed
in multiple counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same agreement. 
 7.11 Descriptive Heading; Interpretation. The descriptive headings in this Agreement are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 
  

					
	COMPANY:	  	PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
			
		  	By:	 	  

		  	Name:	 	Fredric N. Eshelman
		  	Title:	 	Chief Executive Officer

			
	EMPLOYEE:	  	  

		  	Daniel G. Darazsdi

 ANNEX A 
 PROPRIETARY INFORMATION 
 AND INVENTIONS AGREEMENT 
 In consideration and as a condition of my employment by Pharmaceutical Product Development, Inc., a North Carolina corporation, or any affiliate,
subsidiary, successor or assigns, as the case may be (collectively referred to herein as the “Company”), I hereby agree as follows: 
 1. “Proprietary Information” is information that was or is developed by, became or becomes known by, or was or is assigned or otherwise conveyed to the Company, and which has commercial value in the Company’s business.
Proprietary Information includes, without limitation, trade secrets, financial information, product plans, customer lists, marketing plans and strategies, systems, manuals, forecasts and other business information, improvements, inventions, business
strategies, business methods and practices, formulas, product ideas, biological material and techniques for their handling and use, chemical and/or information analysis and related products and data, computer programs and software, software designs
and documentation, source codes, algorithms, techniques, schematics, know-how and data, and any other confidential or proprietary information of the Company or its customers or clients which I have been, or may be exposed to, or have learned or may
learn of from time to time in connection with or as a result of my capacity as an employee of or consultant to the Company, including during the term of this Agreement. Proprietary Information shall not include information that is, through no
improper action or inaction by me, generally available to the public. I understand that my employment creates a relationship of confidence and trust between me and the Company with respect to Proprietary Information of the Company or its customers
which may be learned by me during the period of my employment. 
 2. In consideration of my employment by the Company and the compensation
received by me from the Company from time to time, I hereby agree as follows: 
 (a) All Proprietary Information and all patents, copyrights,
trade secret rights and other rights (including throughout, without limitation, any extensions, renewals, continuations or divisions of any of the foregoing) in connection therewith shall be the sole property of the Company. I hereby assign to the
Company any rights I may have or acquire in such Proprietary Information. At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust and will not use or disclose any Proprietary Information
or anything relating to it without the written consent of the Company, except as may be necessary in the ordinary course of performing my duties to the Company. 
 (b) In the event of the termination of my employment by me or by the Company for any reason, I shall return all documents, records, apparatus, equipment and other physical property, or any reproduction of such
property, whether or not pertaining to Proprietary Information, furnished to me by the Company or produced by myself or others 

 
in connection with my employment, to the Company immediately as and when requested by the Company. 
 (c) I will promptly disclose to the Company, or any persons designated by it, all “Inventions”, which includes all improvements, inventions,
formulas, ideas, works of authorship, processes, computer programs and software, software designs and documentation, algorithms, techniques, schematics, know-how data, whether or not patentable, made or conceived or reduced to practice or developed
by me, either alone or jointly with others, during the term of my employment and for six (6) months thereafter. To the extent the Company does not have rights therein hereunder, such disclosure shall be received by the Company in confidence and
does not extend the assignment made in Section (f) below. 
 (d) During the term of my employment and for [*] thereafter, I will not
encourage or solicit any employee of the Company to leave the Company for any reason or to devote less than all of any such employee’s efforts to the affairs of the Company, provided that the foregoing shall not affect any responsibility I may
have as an employee of the Company with respect to the bona fide hiring and firing of Company personnel. 
 (e) During the term of my
employment and for a period of [*] thereafter, I will not directly or indirectly solicit the business of any client or customer of the Company which I have solicited, negotiated, contracted, serviced or had contact with on the Company’s behalf
for the [*] period prior to the termination of my employment, whether voluntary or involuntary and with or without cause. 
 (f) I agree that
all Inventions which I make, conceive, reduce to practice or develop (in whole or in part, either alone or jointly with others) during my employment shall be the sole property of the Company to the maximum extent permitted by law, and, to the extent
permitted by law, shall be “works made for hire”. The Company shall be the sole owner of all patents, copyrights, trade secret rights, and other intellectual property or other rights in connection therewith. I hereby assign to the Company
any rights I may have or acquire in such Inventions. I agree to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the Company’s expense, in obtaining and enforcing
patents, copyrights, trade secret rights or other rights on such Inventions and/or any other Inventions I have or may at any time assign to the Company in any and all countries. Such acts may include, but are not limited to, execution of documents
and assistance or cooperation in legal proceedings. With respect to any and all matters arising out of or relating to my employment or consultancy with the Company, I hereby irrevocably designate and appoint the Company and its duly authorized
officers and agents, as my agents and attorneys-in-fact to act for and in my behalf and instead of me, to execute and file any applications or related filings and do all other lawfully permitted acts to further the prosecution and issuance of
patents, copyrights, trade secret rights or other rights thereon with the same legal force and effect as if executed by me. 
 (g) I attach
hereto a complete list of all Inventions or improvements to which I claim ownership and/or that I desire to remove from the operation of this 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

 
Agreement, and I covenant that such list is complete. If no such list is attached to this Agreement I represent that I have no such Inventions and
improvements at the time of signing this Agreement. I understand that any such list shall not contain information that breaches an obligation of confidentiality with a former employer. 
 (h) I represent that my performance of all the terms of this Agreement will not breach any agreement or obligation to keep in confidence proprietary
information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith or in conflict with my employment with
the Company. 
 3. The Company agrees that it will not request as part of my employment that I divulge or make use of proprietary information
of any of my former employers that has commercial value to the former employer who developed such information. 
 4. I acknowledge that in
the event of my breach or threatened breach of the terms of this Agreement, the Company shall not have an adequate remedy at law and shall, in addition to any other available rights and remedies, have the right to obtain injunctive relief, including
without limitation specific performance. 
 5. This Agreement shall be effective as of the first day of my employment by the Company, and
shall be binding upon me, my heirs, executors, assigns, and administrators, and shall inure to the benefit of the Company and any current and future affiliates, subsidiaries, successors and assigns. This Agreement supersedes any agreement which may
have been previously made or executed by me relating to this matter. This Agreement shall be governed by the laws of the State of North Carolina (exclusive of conflicts of law provisions), which shall be the venue for resolution of any dispute
related to this Agreement. This Agreement or any part thereof shall not be modified, amended, or waived except by the written consent of the Company’s Chief Executive Officer or President. 
  

							
	Dated:	 	                    , 2007	  	
			
		 	  
	  	
		 	Name: Daniel G. Darazsdi	  	
		
	Accepted and Agreed to:	  	
			
		 	Company	  	
				
		 	By:	 	  
	  	
		 	Name:	 		  	
		 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]